NextCell – Part of the Stem Cell Revolution

Stem and stromal cells are expected to revolutionize the treatment of today’s severe and incurable diseases. NextCell develops pioneering stromal cell therapies for the treatment of autoimmune and inflammatory diseases. NextCell's drug candidate, ProTrans, is at the forefront of our development for the treatment of type 1 diabetes.

NextCell's Product Portfolio

NextCell develops novel stromal cell therapies, with a primary focus on type 1 diabetes. The lead candidate ProTrans, is based on NextCell patented selection algorithm. NextCell also runs Cellaviva, Scandinavia's largest private stem cell bank.

NextCell is a Swedish biopharmaceutical company running two business areas with the same core – stem and stromal cells from umbilical cord. NextCell is focusing on research and development of novel stromal cell therapies and also runs a tissue establishment and primary biobank, classified as a healthcare provider.

Investors

NextCell is listed on the Nasdaq First North Growth Market. Here you will find information about the share, the latest reports and other financial data.

Read our latest report:

Interim Report 1 2024/2025

Download

News

2025-02-19

All Patients with Severe Virus-Induced Pneumonia Treated in the ProTrans V Study

Regulatory

NextCell Pharma AB ("NextCell") announced today that all patients in the clinical trial ProTrans V, where ProTrans is used for the treatment of severe virus-induced pneumonia, have been treated. The study is being conducted at Örebro University Hospital and includes a total of nine patients, with three patients in each dose group.

Read more Read more

2025-01-30

NextCell Pharma publish Interim Report 1 2024/2025

Regulatory

NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 1 for the period September 1, 2024 – November 30, 2024. The report is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-report. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period in the previous year.

Read more Read more

2024-12-17

Long-term Effects with Repeated ProTrans Treatment After 6 Years

Regulatory

NextCell Pharma AB reports new results from the ProTrans-Repeat study, where type 1 diabetes patients have been followed for 5 years after receiving two doses of the stromal cell product ProTrans, in total 6 years after the first infusion. The results show that two out of three patients in the high-dose group increased their insulin production by 23% and 34% respectively.

Read more Read more

2024-12-05

NextCell Pharma changes Certified Adviser to Redeye AB

Regulatory

NextCell Pharma has entered into an agreement with Redeye AB regarding the service as Certified Adviser. Redeye AB will take over as Certified Adviser on January 1, 2025.

NextCell – Part of the Stem Cell Revolution

NextCell's Product Portfolio

About NextCell

Investors

News

All Patients with Severe Virus-Induced Pneumonia Treated in the ProTrans V Study

NextCell Pharma publish Interim Report 1 2024/2025

Long-term Effects with Repeated ProTrans Treatment After 6 Years

NextCell Pharma changes Certified Adviser to Redeye AB

Subscribe to press releases